Light Amplification by Stimulated Emission of Radiation...

Ocular Tumors

Abdussalam Abdullatif Cairo university

The story started long time ago.....

1945

Gerhard Meyer-Schwickerath, a German ophthalmologist



Dr. Meyer carbon arc lamp



as a more reliable artificial light source;

however, a short filament life span, and unpredictable retinal burns limited its usefulness 1950s,

Carl Zeiss Laboratories

xenon arc lamp

It emitted a light spectrum similar to sunlight, with a relatively high, uniform power output.

Ruby Laser was introduced...



Offering a range of wavelengths and pulse durations, and more precisely targeted treatments.

Launching the Laser era Revolution the treatment of retinal disease.

1952 ...

First malignant choroidal melanoma to be treated with laser instead of enucleation

paving the way for laser treatments in ocular oncology

pioneering the use of globe-salvage techniques

The most commonly used:

- Green argon (532 nm),
- Yellow (577 nm)
- Red krypton (660 nm, 670 nm)
- Infrared diode (810 nm)

Longer the wavelength the less scattering the deeper penetration



Infrared diode penetrate to the choroid and sclera.

krypton-red reach the choroid

yellow-diode and argongreen absorbed by RPE shielding the underlying choroid.



Rationale

Laser energy is converted to thermal energy:

> 60 C denatures tissue protein ... coagulative necrosis

> 45-60 ... tissue necrosis without coagulation

TRANSPUPILLARY THERMOTHERAPY PHOTODYNAMIC THERAPY PHOTOCOAGULATION





TRANSPUPILLARY THERMOTHERAPY NEAR-INFRARED DIODE LASER (810 NM)

Duration: Long (1 min) ... thermal effect 45-60C

Power : the energy has been adjusted until gray discoloration of tumor (typically after 30–40 seconds) has been obtained.



TRANSPUPILLARY THERMOTHERAPY NEAR-INFRARED DIODE LASER (810 NM)

 \rightarrow <u>Size</u>: up to <u>2.5 mm</u> in depth,

Application: the entire surface of the tumor and 1.5 mm margins of normal appearing tissue around the tumor

HISTOPATHOLOGICALLY

Cells with shrunken nuclei without nucleoli, and loss of cytoplasm.

Blood vessels are typically both dilated and occluded by thrombi.

Bleaching of erythrocytes, tumor nuclear debris with no cytoplasm.



CHOROIDAL MELANOMA

RETINOBLASTOMA

Uveal Melanoma Management

- Small tumors.....observe/ TTT
- Medium sized tumor....Brachytherapy
- Large sized tumor....Enculeation

CHOROIDAL MELANOMA

<u>Indications</u>

Primary therapy for small tumors
 -Less than 10 mm in basal diameter
 -Less than 2.5 mm in thickness



<u>CHOROIDAL MELANOMA</u> <u>Indications</u>

- Treatment of marginal tumor recurrence
- Treatment of residual tumor



CHOROIDAL MELANOMA

<u>Indications</u>

- Combined with plaque radiotherapy ("sandwich procedure")
- □ Medium sized tumors beyond brachytherapy















CHOROIDAL MELANOMA

Contraindications

- Significant media opacities:
 corneal opacities, cataract, or hge
- > Poor pupillary dilation or difficulty positioning patient
- Amelanotic tumors tend to have poor response

RETINOBLASTOMA

Mainstay is chemotherapy

Intravenous Intra arterial Intravitreal



<u>RETINOBLASTOMA</u> <u>Indications</u>

 Primary laser therapy for (Grade A tumors)
 Small tumors greater than 3 mm from the fovea and greater than 1.5 mm from optic disk
 Less than 3 mm in basal diameter and height



<section-header><section-header><section-header>

<u>RETINOBLASTOMA</u> Indications

Combined with chemotherapy (Grade A–D tumors)



<u>RETINOBLASTOMA</u> <u>Indications</u>

- Treatment of marginal tumor recurrence
- Treatment of residual tumor

<u>RETINOBLASTOMA</u>

- Extraocular extension
- Tumor involving the optic nerve
- Grade E tumors-destined for enucleation



PHOTODYNAMIC THERAPY

PDT

<u>Non-thermal, dye-activating laser</u> light

photosensitizing agent is activated by PDT laser light.

In the presence of oxygen, the resultant reaction destroys cells (<u>APOPTOSIS</u>) and closes blood vessels (<u>NECROSIS</u>).



PDT dye is dependent upon tumor perfusion.



LASER-BASED COMPONENT DEPENDENT UPON TUMOR PIGMENTATION AND THICKNESS

TAP PROTOCOL

IV infusion of 6 mg/m2 over 10 minutes.

After 5 minutes

690 nm laser at an intensity of 600 mW/cm2

for 83 sec per application.

This results in delivery of 50 J/cm2 of energy



CIRCUMSCRIBED CHOROIDAL HEMANGIOMA



Management

- Asymptomatic ... Observation
- Symptomatic ... treat

CIRCUMSCRIBED CHOROIDAL HEMANGIOMA

Indications

 Subretinal fluid and serous retinal detachment threatening the fovea

Visual symptoms associated with the lesion

Management

Transpupillary Thermotherapy

Thickness < 4mm Shallow SRF Extrafoveal

Management

PDT

Better option with better visual outcome

Shield et al reviewed 458pts and found that patients in PDT era has better visual outcome 20/63 than in pre PDT era 20/400





Retinal Capillary hemangioma

treatment depend on:

- Size,
- Location,
- Degree of exudation,
- Presence of retinal detachment,
- Associated epiretinal fibrosis or hemorrhage

Retinal Capillary hemangioma

Size < 1.5 mm (1DD) No Fluid Post equatorial

LASER PHOTOCOAGULATION

Retinal Capillary hemangioma

Laser Photocoagulation

In a series of 174 RCH, successful ablation was reported for 100% tumors with diameter of 1.5 mm or less, compared with 47% larger RH

Retinal Capillary hemangioma

Laser Photocoagulation

Parameters: Argon green laser

- Duration: 0.4-0.8 sec
- Spot size: 200-500
- Power: whitening
- Surface of tumor ± feeding vessels



More Indications

- Treatment of radiation retinopathy
- Treatment of tumor related glaucoma
- Treatment of post radiation rise in IOP

Laser complications:

- RD 4%
- Traction 13%
- Vit hge 1.3
- CME 2%
- Vascular occlusion 29%
- CNV



TAKE HOME MESSAGE

- Lasertherapy has advanced to become an important tool in the armamentarium in the management of intraocular neoplasms
- Lasers offer many advantages, serving as primary and adjuvant treatments for a variety of different tumors.
- Laser therapy is usually well tolerated and allows the practitioner to selectively target the tumor by direct visualization.

